-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Amyotrophic Lateral Sclerosis in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amyotrophic Lateral Sclerosis in Amyotrophic Lateral Sclerosis Drug Details: Monoclonal antibody is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LP-0200 in Psoriasis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LP-0200 in Psoriasis Drug Details:LP-0200 is under development for the treatment of psoriasis. It acts by...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Izuforant in Atopic Dermatitis (Atopic Eczema)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Izuforant in Atopic Dermatitis (Atopic Eczema)Drug Details:Izuforant is under development for the treatment of atopic dermatitis and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rheumatoid Arthritis in Rheumatoid Arthritis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rheumatoid Arthritis in Rheumatoid Arthritis Drug Details: The therapeutic candidate is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JWP-1601 in Atopic Dermatitis (Atopic Eczema)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JWP-1601 in Atopic Dermatitis (Atopic Eczema) Drug Details: JWP-1601 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-74699157 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-74699157 in Non-Small Cell Lung Cancer Drug Details: JNJ-74699157 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FOR-46 in Refractory Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FOR-46 in Refractory Multiple Myeloma Drug Details: FOR-46 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LP-0145 in Atopic Dermatitis (Atopic Eczema)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LP-0145 in Atopic Dermatitis (Atopic Eczema) Drug Details:LP-0145 (ARGX-112) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Polmacoxib + Tramadol) in Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Polmacoxib + Tramadol) in Pain Drug Details: CG-650 is a fixed dose combination of polmacoxib...
-
Product Insights
New![]()
X-Linked Hypophosphatemic Rickets Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
X-Linked Hypophosphatemic Rickets Clinical Trials Overview The X-Linked Hypophosphatemic Rickets clinical trial report consists of 55 trials. The report provides an overview of the X-Linked Hypophosphatemic Rickets clinical trial scenario. The report provides top-line data relating to the clinical trials on X-Linked Hypophosphatemic Rickets. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.